行情

CFRX

CFRX

ContraFect
NASDAQ

实时行情|Nasdaq Last Sale

2.360
-0.080
-3.28%
盘后: 2.360 0 0.00% 17:08 01/21 EST
开盘
2.400
昨收
2.440
最高
2.510
最低
2.280
成交量
9.74万
成交额
--
52周最高
7.63
52周最低
2.280
市值
9,282.52万
市盈率(TTM)
-3.4650
分时
5日
1月
3月
1年
5年
ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis
 ContraFect Corporation (NASDAQ:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical
Benzinga · 01/06 21:21
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...
GlobeNewswire · 01/06 21:05
How Much Of ContraFect Corporation (NASDAQ:CFRX) Do Institutions Own?
A look at the shareholders of ContraFect Corporation ( NASDAQ:CFRX ) can tell us which group is most powerful...
Simply Wall St. · 01/01 12:23
Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases
Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in ChildrenYONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: C...
GlobeNewswire · 2021/12/20 14:00
BRIEF-ContraFect Files For Offering Of 8.8 Mln Shares Of Common Stock
reuters.com · 2021/12/08 22:18
From Benzinga's Global Small Cap Conference: Worksport CEO, Steven Rossi Says 'We Are Deploying Capital For Inventory From China, We Are Launching Wokrsport.com A Direct To Customer Website'
https://www.youtube.com/watch?v=XkOilNZqoEI
Benzinga · 2021/12/08 15:06
CFRX:直接裂解剂显示出对革兰氏阴性病原体的体外活性……
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT
Benzinga · 2021/12/05 11:11
Contrafect EPS beats by $0.15
Contrafect (NASDAQ:CFRX): Q3 GAAP EPS of -$0.13 beats by $0.15. Cash, cash equivalents and marketable securities of $63.3M. Press Release
Seekingalpha · 2021/11/15 13:39
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CFRX最新的财务预测,通过CFRX每股收益,每股净资产,每股现金流等数据分析ContraFect近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

25.00%强力推荐
75.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CFRX价格均价为13.58,最高价位23.00,最低价为6.50。
最高23.00
均价13.58
最低6.50
现价2.360
EPS
实际EPS
预期EPS
-0.25-0.19-0.12-0.06
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 78
机构持股: 2,851.85万
持股比例: 72.51%
总股本: 3,933.27万
类型机构数股数
增持
8
33.86万
建仓
6
7.21万
减持
15
19.06万
平仓
17
89.07万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
Chairman/President/Chief Executive Officer/Director
Roger Pomerantz
Vice Chairman/Director
Steven Gilman
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
Senior Vice President
Gary Woodnutt
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Independent Director
Lishan Aklog
Independent Director
Jane Barlow
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
暂无数据
CFRX 简况
ContraFect Corp是一家临床阶段的生物技术公司。该公司专注于发现和开发包括溶素和阿穆林肽的直接裂解剂(DLA),作为治疗危及生命的抗生素耐药性感染的新医疗方式。其主要的DLA候选药物包括exebacase,这是一种针对金黄色葡萄球菌(Staph aureus)的研究性新型溶素,该药物包括耐甲氧西林(MRSA)菌株,该菌株会导致如菌血症、肺炎和骨髓炎的严重感染。其溶素候选产品CF-301用于治疗由耐甲氧西林金黄色葡萄球菌和敏感金黄色葡萄球菌菌株引起的金黄色葡萄球菌菌血症,包括心内膜炎。该公司正在进行exebacase的II期临床研究,用于治疗由MRSA或甲氧西林敏感金黄色葡萄球菌(MSSA)引起的金黄色葡萄球菌菌血症,包括右侧心内膜炎。

微牛提供ContraFect Corp(NASDAQ-CFRX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CFRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CFRX股票基本功能。